Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Given Average Rating of "Hold" by Analysts

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT - Get Free Report) have earned an average rating of "Hold" from the eight analysts that are covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $34.3333.

Several equities analysts have recently issued reports on the company. Wall Street Zen lowered Lakefront Biotherapeutics American Depositary Shares from a "buy" rating to a "hold" rating in a research note on Saturday, May 16th. Weiss Ratings downgraded Lakefront Biotherapeutics American Depositary Shares from a "hold (c)" rating to a "hold (c-)" rating in a research report on Tuesday, August 4th. Morgan Stanley initiated coverage on Lakefront Biotherapeutics American Depositary Shares in a research note on Friday, July 10th. They issued an "equal weight" rating and a $30.00 price objective on the stock. Finally, Zacks Research upgraded Lakefront Biotherapeutics American Depositary Shares from a "strong sell" rating to a "hold" rating in a research report on Monday, June 8th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LKFT. State of Wyoming bought a new position in Lakefront Biotherapeutics American Depositary Shares during the 2nd quarter worth approximately $28,000. Van ECK Associates Corp lifted its position in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% in the 4th quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 750 shares during the period. Arax Advisory Partners boosted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% in the 4th quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company's stock valued at $76,000 after purchasing an additional 1,778 shares during the last quarter. Quadrant Capital Group LLC bought a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter valued at $134,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the third quarter worth $211,000. Institutional investors and hedge funds own 32.46% of the company's stock.

Lakefront Biotherapeutics American Depositary Shares Trading Down 0.3%

Lakefront Biotherapeutics American Depositary Shares stock opened at $26.91 on Tuesday. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of -19.09 and a beta of 0.27. Lakefront Biotherapeutics American Depositary Shares has a 12 month low of $25.68 and a 12 month high of $37.78. The stock's 50 day moving average is $28.65 and its 200-day moving average is $30.11.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT - Get Free Report) last announced its earnings results on Monday, August 10th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.97) by $1.01. The business had revenue of $15.47 million during the quarter, compared to the consensus estimate of $7.29 million. As a group, equities research analysts predict that Lakefront Biotherapeutics American Depositary Shares will post -10.83 earnings per share for the current fiscal year.

Lakefront Biotherapeutics American Depositary Shares Company Profile

Galapagos NV NASDAQ: GLPG is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company's discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company's pipeline encompasses multiple programs across various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source